Related references
Note: Only part of the references are listed.Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
John D. Martin et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 81 (2019)
Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models
Sushil Kumar et al.
TRANSLATIONAL ONCOLOGY (2018)
Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
Kaitlin Graham et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
Ishna N. Mistry et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the Low Drug Uptake Volume
Ala Yaromina et al.
RADIOTHERAPY AND ONCOLOGY (2017)
A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model
Carla Hajj et al.
TRANSLATIONAL ONCOLOGY (2017)
Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
Shujing Liu et al.
ONCOTARGET (2017)
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
Katarzyna J. Nytko et al.
ONCOTARGET (2017)
A mathematical model of tumor hypoxia targeting in cancer treatment and its numerical simulation
Muhammad Sabir et al.
COMPUTERS & MATHEMATICS WITH APPLICATIONS (2017)
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Soo Jung Kim et al.
CANCER LETTERS (2017)
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Natalia Baran et al.
CLINICAL CANCER RESEARCH (2017)
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2016)
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Roger M. Phillips
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
Ewa Maj et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
Ines Lohse et al.
ONCOTARGET (2016)
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
C. Yoon et al.
BRITISH JOURNAL OF CANCER (2015)
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Sarah G. J. A. Peeters et al.
CLINICAL CANCER RESEARCH (2015)
The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic
E. M. Hammond et al.
CLINICAL ONCOLOGY (2014)
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Christopher P. Guise et al.
CHINESE JOURNAL OF CANCER (2014)
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Qian Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Jessica D. Sun et al.
CLINICAL CANCER RESEARCH (2012)
Modeling the Spatial Distribution of Chronic Tumor Hypoxia: Implications for Experimental and Clinical Studies
Gibin Powathil et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
Jean-Philippe Cosse et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2008)
Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies
M. Kohandel et al.
PHYSICS IN MEDICINE AND BIOLOGY (2007)
Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy
G. Powathil et al.
PHYSICS IN MEDICINE AND BIOLOGY (2007)
The evolution of mathematical Modeling of glioma proliferation and invasion
Hana L. P. Harpold et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel et al.
CANCER AND METASTASIS REVIEWS (2007)
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs
Kevin O. Hicks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
M Franco et al.
CANCER RESEARCH (2006)
Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors
KM Laginha et al.
CLINICAL CANCER RESEARCH (2005)
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
S Sengupta et al.
NATURE (2005)
Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy?
L Harrison et al.
ONCOLOGIST (2004)
Imaging of angiogenesis: from microscope to clinic
DM McDonald et al.
NATURE MEDICINE (2003)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects
M Höckel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
